Genç Akciğer Kanseri Hastalarından Alınan Doku ve Kan Örneklerinde Kapsamlı Genomik Analiz

Sade dilde özet

Bu çalışma, genç akciğer kanseri (lung cancer) hastalarında tümör ve kan örneklerinin kapsamlı genetik (genomik) analizini araştırıyor. Küçük hücreli veya küçük hücreli dışı akciğer kanseri patolojik olarak doğrulanmış hastalar dahil edilmiştir. Faz uygulanmayan gözlemsel bir çalışmadır ve tamamlanmıştır.

Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.

Deney bilgileri

Faz

N/A

Durum

Tamamlandı

Sponsor

University of Southern California

Müdahale

cytology specimen collection procedure, laboratory biomarker analysis

Başlangıç

22.07.2014

Tahmini bitiş

08.09.2020

Ülkeler

United States

İlgili genler

Merkezler

• Los Angeles, United States
• Boston, United States

Uygunluk kriterleri

Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.

Inclusion Criteria:

* COHORT 1: LUNG CANCER PATIENTS
* Pathologically confirmed bronchogenic lung carcinoma (small cell lung cancer \[SCLC\] or non-small cell lung cancer \[NSCLC\] of any stage) at any treatment time point
* For individuals diagnosed with advanced disease (stage IV or recurrent) enrollment must occur within 2 years of diagnosis
* For appropriate patients (stage IV non-squamous NSCLC) epidermal growth factor receptor (EGFR ) and anaplastic lymphoma kinase (ALK) genotyping performed by a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory is recommended prior to participation
* Provision of written informed consent
* Willingness to undergo a single blood draw
* Individuals who are under 18 are eligible for study if they meet the defined criteria for cohort 1; in addition, consent for participation must be given by a legal guardian or parent

  * NOTE: to be eligible for genomics, availability of 10 unstained slides (plus hematoxylin and eosin \[H\&E\] slide) or an adequate formalin-fixed paraffin-embedded (FFPE) tumor block from clinically indicated interventional procedures is required
* COHORT 2: DECEASED INDIVIDUALS
* Deceased individuals diagnosed with lung cancer at any age less than 40 may be studied on a case by case basis depending upon Institutional Review Board (IRB) approval at a participating institution; inclusion will require availability of adequate archived FFPE tissue and release of tissue and records by next of kin, if available

Exclusion Criteria:

* Compromise of patient diagnosis or staging if tissue is used for research